In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 65 for your search:

Drug:  bicalutamide
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Casodex/Zoladex Biomarkers in Localised Prostate Cancer

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: D6876C00001, NCT00293696

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 40 to 90
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVO108943, NCT00470834

Phase III Randomized Study of Radical Prostatectomy with vs without Neoadjuvant Hormone Therapy Using Leuprolide or Goserelin and Flutamide or Bicalutamide for Stage I/II Prostate Cancer (Summary Last Modified 08/98)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: NCI
Protocol IDs: SWOG-S9615, SWOG-9615, S9615

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: no age specified
Sponsor: NCI, Other
Protocol IDs: DM95-231, P30CA016672, MDA-DM-95231, NCI-G96-1044, CDR0000065105, NCT00002855

Phase III Randomized Study of Radiotherapy With Or Without Bicalutamide in Patients With PSA Elevation Following Radical Prostatectomy for Carcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI
Protocol IDs: RTOG-9601, RTOG 96-01, RTOG-R9601, NCT00002874, RTOG-96-01

Phase III Study of Total Androgen Suppression Versus Total Androgen Suppression Plus Definitive External Beam Irradiation for Pathologic Lymph Node Positive Adenocarcinoma of the Prostate (Summary Last Modified 11/98)

Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: RTOG-9608, RTOG-96-08

Hormone Therapy in Treating Patients With Advanced Prostate Cancer

Phase: Phase III
Type: Health services research, Treatment
Status: Completed
Age: Any age
Sponsor: Other
Protocol IDs: EORTC-22961, EORTC-GU-22961, NCT00003026

Phase III Randomized Study of Bicalutamide versus Placebo in Combination with Castration as Second Line Therapy in Patients with Asymptomatic Metastatic Prostate Cancer (Summary Last Modified 01/2000)

Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: MSKCC-98092, ZENECA-7054US/0007, NCI-G99-1494

Phase III Randomized Study of Androgen Suppression and Radiotherapy With or Without Subsequent Paclitaxel, Estramustine, and Etoposide in Patients With Localized High-Risk Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: RTOG-9902, RTOG-DEV-1020, RTOG-99-02, NCT00004054

10.

Phase III Randomized Study of Neoadjuvant Total Androgen Suppression and Radiotherapy in Patients With Intermediate-Risk Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-9910, NCT00005044, RTOG-99-10

11.

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 80 and under
Sponsor: Other
Protocol IDs: CDR0000068749, EORTC-22991, NCT00021450

12.

Phase III Randomized Adjuvant Study of Radiotherapy With Hormonal Therapy Versus Radiotherapy Alone in Patients With High-Risk Stage II or III Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: RTOG-P-0011, RTOG-DEV-1037, CAN-NCIC-PR9, NCT00023829, PR9

13.

Phase III Randomized Study of Androgen Blockade With Concurrent Chemotherapy Versus Delayed Chemotherapy in Patients With High-Risk Hormone-Naive Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-P-0014, RTOG-DEV-1028, ECOG-RTOG-P-0014, CALGB-RTOG-P-0014, SWOG-RTOG-P-0014, NCT00030654

14.

Phase III Randomized Comparison of Casodex vs ZDX or Orchiectomy in Patients with Previously Untreated Stage D2 Adenocarcinoma of the Prostate

Phase: Phase III
Type: Treatment
Status: Closed
Age: 30 and over
Sponsor:
Protocol IDs: UCLA-9002048, NCI-V90-0176

15.

Phase III Randomized Study of Orchiectomy vs Casodex (ICI 176334) in Patients with Metastatic Prostate Cancer (Summary Last Modified 03/92)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CRC-TU-PR3003, EU-90044

16.

Phase III Randomized Trial of Casodex vs Flutamide in Combination with either Leuprolide or Goserelin in Patients with Previously Untreated Stage D2 Prostatic Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: over 18
Sponsor:
Protocol IDs: MSKCC-92050, NCI-V92-0124

17.

Phase III Randomized Trial of Two Different Doses of Casodex (100 vs 150 mg/day) vs Orchiectomy or Medical Castration with ZDX in Patients with Advanced Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: CRC-TU-PR3005, EU-92015

18.

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 80
Sponsor: Other
Protocol IDs: CDR0000270970, FRE-FNCLCC-GETUG-12/0203, EU-20238, NCT00055731

19.

Phase III Randomized Study of High-Dose Intensity-Modulated Radiotherapy Alone Versus With Neoadjuvant and Adjuvant Androgen Deprivation Comprising Bicalutamide and Goserelin in Patients With High-Grade Intermediate-Risk or Unfavorable-Risk Adenocarcinoma of the Prostate

Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-03040, NCT00067015

20.

Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer

Phase: Phase III
Type: Prevention, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: 7054IT/0003, NCT00233610

21.

Phase III Randomized Study of Androgen Suppression (AS) and Radiotherapy (RT) Versus AS and RT Followed by Docetaxel and Prednisone in Patients With Localized, High-Risk Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0521, NCT00288080

22.

Androgen Suppression Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With High-Risk Localized Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Other
Protocol IDs: PR12, CAN-NCIC-PR12, CDR0000589247, NCT00651326

23.

Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS30, 2008-005232-33 (EudraCT No), NCT00833248

24.

Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: FE200486 CS31, 2008-008604-40, NCT00884273

25.

Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 80
Sponsor: NCI, Other
Protocol IDs: PR3, CAN-NCIC-PR3, ECOG-JPR03, MRC-PR07, SWOG-JPR3, EU-99013, NCI-T94-0110O, ISRCTN24991896, CDR0000064065, CALGB-9593, T94-0110, NCT00002633

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®